Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Krystal Biotech, Inc. (KRYS : NSDQ)

• Company Description    Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. Number of Employees: 275

• Price / Volume Information    Yesterday's Closing Price: $283.29 Daily Weekly Monthly 20 Day Moving Average: 279,128 shares Shares Outstanding: 29.23 (millions) Market Capitalization: $8,281.19 (millions) Beta: 0.49 52 Week High: $298.30 52 Week Low: $122.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.95% -1.03% 12 Week 29.53% 28.24% Year To Date 14.91% 14.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2100 WHARTON STREET SUITE 701 - PITTSBURGH,PA 15203 USA ph: 412-586-5830 fax: - investors@krystalbio.com http://www.krystalbio.com

• General Corporate Information    Officers Krish S. Krishnan - Chief Executive Officer; President and Director Suma M. Krishnan - President Kathryn A. Romano - Chief Accounting Officer Daniel S. Janney - Director Julian Gangolli - Director Peer Information Krystal Biotech, Inc. (CORR.) Krystal Biotech, Inc. (RSPI) Krystal Biotech, Inc. (CGXP) Krystal Biotech, Inc. (BGEN) Krystal Biotech, Inc. (GTBP) Krystal Biotech, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501147102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/05/26 Share - Related Items Shares Outstanding: 29.23 Most Recent Split Date: (:1) Beta: 0.49 Market Capitalization: $8,281.19 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $1.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $8.46 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/05/26

• Fundamental Ratios P/E Current FY Estimate: 33.50 Trailing 12 Months: 41.36 PEG Ratio: - Price Ratios Price/Book: 6.74 Price/Cash Flow: 38.86 Price / Sales: 21.28 EPS Growth vs. Year Ago Period: 11.84% vs. Previous Quarter: -36.09% Sales Growth vs. Year Ago Period: 17.52% vs. Previous Quarter: 9.51% ROE 12/31/25 - 18.69 09/30/25 - 19.36 06/30/25 - 15.21 ROA 12/31/25 - 17.12 09/30/25 - 17.65 06/30/25 - 13.81 Current Ratio 12/31/25 - 9.95 09/30/25 - 10.14 06/30/25 - 9.68 Quick Ratio 12/31/25 - - 09/30/25 - 9.73 06/30/25 - 9.33 Operating Margin 12/31/25 - 52.64 09/30/25 - 53.30 06/30/25 - 40.85 Net Margin 12/31/25 - 52.64 09/30/25 - 53.30 06/30/25 - 40.85 Pre-Tax Margin 12/31/25 - 48.69 09/30/25 - 50.10 06/30/25 - 46.98 Book Value 12/31/25 - 41.72 09/30/25 - 39.24 06/30/25 - 35.96 Inventory Turnover 12/31/25 - 0.66 09/30/25 - 0.68 06/30/25 - 0.90 Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©